Is the price fair?
What VRTX's price assumes
Vertex Pharmaceuticals trades at 31.9× earnings against 32.4× for the median Biotechnology name, cheaper than its own group.
31.9
Trailing P/E · Biotechnology median 32.4 · cheaper than the typical name in its group
- Price / sales
- 9.37
Price / sales · as of 2026-Q1
- Free cash flow yield
- 3.3%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +11%
Growth the price implies · The price pays for +11% free cash flow growth a year for a decade; the business has delivered −0.71% a year over the last three.
Details›
- Price / book2026-Q1
- 5.91
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Free cash flow, trailing twelve months
- $3.80B
- Market capitalisation
- $114.6B
- 3-year revenue growth
- +9.8%
- 3-year free cash flow growth
- −0.71%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $417.85 |
| Its own P/E history, median | $474.43 |
| Its own P/E history, upper quartile | $637.41 |
| 52-week range | $366.54 – $553.04 |
| Today | $547.27 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.